Adaptive Biotechnologies Corporation (ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced a partnership with Illumina, Inc. (ILMN) to develop in-vitro diagnostic (IVD) test kits for Adaptive’s current and future portfolio of next-generation sequencing (NGS)-based immunodiagnostics. The test kits under development would expand the availability of Adaptive’s clonoSEQ® Assay for assessing and monitoring minimal residual disease (MRD) for the management of patients with certain blood cancers and immunoSEQ Dx™ Assay for pipeline applications.
blaineonline.finance.blog 